NASDAQ:IMCC IM Cannabis Q2 2025 Earnings Results & Report $1.33 -0.13 (-8.90%) As of 02:31 PM Eastern This is a fair market value price provided by Massive. Learn more. IM Cannabis beat analyst earnings expectations but missed on revenue in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$1.9578 versus the -$4.1004 consensus estimate, while revenue of $9.21 million fell short of the $12.88 million estimate by $3.67 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market OpensConference Call9:00 AM ET IM Cannabis EPS ResultsActual EPS-$1.9578Consensus EPS -$4.1004Beat/MissBeat by +$2.1426One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersIM Cannabis Revenue ResultsActual Revenue$9.21 millionExpected Revenue$12.88 millionBeat/MissMissed by -$3.67 millionYoY Revenue GrowthN/AUpcoming EarningsIM Cannabis' Q3 2026 earnings is estimated for Monday, November 16, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) IM Cannabis Q2 2025 Earnings FAQ Did IM Cannabis beat earnings estimates for Q2 2025? IM Cannabis (NASDAQ:IMCC) reported earnings of -$1.9578 per share for Q2 2025, beating the consensus estimate of -$4.1004. The report was announced on Tuesday, August 12, 2025. What was IM Cannabis' revenue for Q2 2025? IM Cannabis reported revenue of $9.21 million for Q2 2025, against a consensus estimate of $12.88 million. When is IM Cannabis' next earnings date? IM Cannabis' next earnings date is estimated for Monday, November 16, 2026. MarketBeat tracks confirmed and estimated earnings dates for IM Cannabis on the company's earnings history page. IM Cannabis Earnings HeadlinesIM Cannabis (NASDAQ:IMCC) Stock Rating Lowered by Wall Street ZenOctober 10 at 1:31 AM | americanbankingnews.comIM Cannabis Announces Closing of the Sale of IMC Holdings and Its European-Focused Operations, Strengthens Balance SheetSeptember 29, 2026 | prnewswire.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.October 13 at 1:00 AM | Decentralized Masters (Ad)IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common SharesSeptember 24, 2026 | prnewswire.comIM Cannabis Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 23, 2026 | prnewswire.comIM Cannabis prices $1.31M registered direct offeringSeptember 23, 2026 | msn.comSee More IM Cannabis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IM Cannabis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IM Cannabis and other key companies, straight to your email. Email Address About IM CannabisIM Cannabis (NASDAQ:IMCC) is a medical cannabis company focused on the cultivation, importation, distribution and sale of cannabis products. The company markets products under the IMC brand and serves patients through regulated medical cannabis channels. IM Cannabis operates primarily in Israel and Germany. In Israel, the company’s activities include supplying medical cannabis products through pharmacies and other authorized distribution channels. In Germany, it participates in the medical cannabis market through the importation and distribution of pharmaceutical-grade products. The company was established in 2018 and has developed its business through subsidiaries and strategic partnerships in its target markets. Its operations are subject to the regulatory requirements governing medical cannabis cultivation, processing, importation and dispensing in each jurisdiction.View IM Cannabis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season NearsMarketBeat Week in Review – 10/05 - 10/09 Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
